Navigation Links
Prostacyclin analogs and PDE 5 inhibitors synergistically stimulate ATP release from human RBCs
Date:9/20/2013

Researchers at Saint Louis University School of Medicine have discovered a novel interaction between prostacyclin (PGI2) analogs and phosphodiesterase 5 (PDE5) inhibitors, two groups of drugs used in the treatment of pulmonary arterial hypertension (PAH). They found that, in combination, these drugs stimulate enhanced release of a potent vasodilator adenosine triphosphate (ATP) from human red blood cells (RBCs). Their study appears in the September 2013 issue of Experimental Biology and Medicine.

PAH is a chronic disorder characterized by sustained increases in pulmonary vascular resistance leading to pulmonary hypertension and right ventricular heart failure. Although the pathophysiology of PAH is not fully understood, the condition has a poor prognosis in the absence of pharmacological intervention. The major classes of drugs used to treat severe PAH include both PGI2 analogs and PDE5 inhibitors.

It is widely accepted that in vascular smooth muscle cells, PGI2 analogs dilate blood vessels by increasing cyclic adenosine 3',5' mono-phosphate (cAMP) while PDE5 increases cyclic guanosine 3',5' mono-phosphate (cGMP) by inhibiting its breakdown. However, human erythrocytes also express functional prostacyclin receptors (IPRs) and possess PDE5. The binding of PGI2 analogs to the erythrocyte IPR activates a well-defined signaling pathway that stimulates increases in cAMP and culminates in the release of the vasoactive molecule, adenosine 3'5' triphosphate (ATP). When released from circulating erythrocytes in the vascular lumen, ATP binds to receptors on the endothelium of pulmonary vessels resulting in the synthesis of vasodilators. Importantly, the levels of cAMP in the erythrocyte IPR signaling pathway are regulated by PDE3, a PDE that is inhibited by cGMP. Levels of cGMP in erythrocytes are regulated by PDE5.

Dr. Randy Sprague, senior author of this article, said "We hypothesized that increases in cGMP resulting from PDE5 inhibition would prevent the breakdown of IPR-mediated increases in cAMP leading to enhanced ATP release. The major finding of this study is that either of two chemically dissimilar inhibitors of PDE5 augment increases in cAMP and ATP release produced by incubation of erythrocytes with an IPR agonist, UT-15C (treprostinil). Dr. Stephanie Knebel, first author, said "Our results demonstrate a new role for both prostacyclin analogs and PDE5 inhibitors in the regulation of IPR-mediated increases in cAMP and ATP release from human erythrocytes." These findings have implications for the development of new therapeutic approaches to the treatment of conditions such as pulmonary arterial hypertension.

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine, said "This intriguing study by Knebel et al has demonstrated that both PDE5 inhibitors and prostacyclin analogs are involved in the prostacyclin receptor dependent release of cAMP and ATP for human RBCs. Their results suggest new therapeutic approaches for the treatment of pulmonary arterial hypertension".


'/>"/>

Contact: Stephanie M. Knebel
knebelsm@slu.edu
Society for Experimental Biology and Medicine
Source:Eurekalert

Related medicine news :

1. Possible predictive biomarker for patients who may respond to autophagy inhibitors
2. Agios research demonstrates the effects of mutant IDH1 and IDH2 inhibitors in primary tumor models
3. Cisplatin-resistant cancer cells sensitive to experimental anticancer drugs, PARP inhibitors
4. Biomarker may identify neuroblastomas with sensitivity to BET bromodomain inhibitors
5. Researchers use new molecular inhibitors to successfully hit difficult cancer target
6. New mechanism of action for PARP inhibitors discovered
7. PARP inhibitors may have clinical utility in HER2-positive breast cancers
8. Preclinical data support ongoing clinical trials testing IDO inhibitors as a treatment for cancer
9. Inhibitors of shuttle molecule show promise in acute leukemia
10. Fountain Valley, CA Gum Disease Treatment with Dr. Robert Mokbel Now Utilizes the FDA-cleared Laser to Stimulate Bone Growth and Can Prevent Tooth Loss
11. Fort Worth Dental Now Offers Laser Gum Disease Treatment to Stimulate Bone Regrowth and Possibly Save Natural Teeth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... 27, 2017 , ... New patients who have sleep apnea in ... or without a referral. Sleep apnea is often left untreated because patients are not ... and chronic snoring. , Dr. Braasch seeks to raise awareness of sleep apnea ...
(Date:3/27/2017)... ... 27, 2017 , ... Drs. Bruce Trimble and Michelle Parker ... a referral. Trimble Dental offers a variety of services to meet each patient’s ... patients have discolored, crooked or missing teeth in Eau Claire, WI, Drs. Trimble ...
(Date:3/27/2017)... ... 2017 , ... Drs. Justin Kolnick, Kara Diamond, Randall Barton, Keith Hope and ... key role this treatment plays in protecting oral health, along with the benefits of ... who need a root canal in White Plains, NY or their second location in ...
(Date:3/27/2017)... ... 2017 , ... This is the second major release since ... 2014. It is the culmination of collaborative efforts by members of the OSEHRA ... Member Zato Health co-funded the ONC certification and provided key technical support throughout ...
(Date:3/27/2017)... ... March 27, 2017 , ... SyncDog, ... co-exhibit with technology partners LG Business Solutions at ATARC Federal Mobile Computing ... Washington D.C., will provide education and examination into the mobility tools and technology ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... WAUKESHA, Wis. , March 27, 2017  A ... one of only four freestanding hospitals in the country ... in plastic and reconstructive surgery, concluded that the Surfacide ... effective and integral component in reducing bacterial pathogens not ... The findings were published at the American Burn Association,s ...
(Date:3/27/2017)... March 27, 2017 Medtec ... and more than 600 exhibitors from 70 countries ... and solutions that will advance the medical technology ... at the Messe Stuttgart, Stuttgart, Germany ... technology platform showcasing the key trends and insights ...
(Date:3/27/2017)... British Columbia, March 27, 2017  Sophiris Bio ... or "Sophiris"), a clinical late-stage biopharmaceutical company developing ... urological diseases, today reported fourth quarter and full ... Key Corporate Highlights: ... Localized Prostate Cancer. During 2016, the Company reported ...
Breaking Medicine Technology: